HPTA
Hypothalamic–Pituitary–Testicular Axis. The negative-feedback loop that runs endogenous testosterone. Shut down by every AAS cycle.
The Hypothalamic-Pituitary-Testicular Axis — HPTA, or HPG when referenced in the broader gonadal-endocrinology literature — is the negative-feedback loop that governs endogenous androgen production.
The signalling cascade, in order:
1. Hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses at ~90-minute intervals. Pulse frequency, not amplitude, encodes the signal.
2. Anterior pituitary responds to GnRH pulses with pulsatile LH and FSH secretion into portal circulation.
3. Testicular Leydig cells respond to LH by synthesising testosterone from cholesterol via the steroidogenic pathway. Sertoli cells respond to FSH by supporting spermatogenesis in seminiferous tubules.
4. Circulating testosterone — and more potently its estradiol metabolite — feeds back negatively at both hypothalamic and pituitary levels, suppressing further GnRH and LH/FSH release.
Exogenous androgen administration breaks the loop. Serum testosterone rises into the supraphysiological range; the hypothalamus registers chronic saturation; GnRH pulsing ceases; LH and FSH drop below detection limits within 14 days on standard testosterone protocols. Without LH drive, Leydig cells atrophy — visible as testicular volume reduction within 4–6 weeks. Without FSH, spermatogenesis halts; sperm count falls toward azoospermia within 8–12 weeks on most cycles.
PCT targets the negative-feedback block. SERMs (tamoxifen, clomiphene) occupy estrogen receptors at the hypothalamus without agonist activity, removing the feedback brake and restoring GnRH pulsing. hCG is an LH analogue — it directly stimulates Leydig cells, bypassing the hypothalamus. The distinction matters clinically: hCG restores testicular testosterone synthesis without restarting the central signal; SERMs restart the central signal but require responsive Leydig cells to work. Long suppression produces Leydig desensitisation, which is why extended cycles benefit from on-cycle hCG (500 IU 2× weekly) to maintain responsive tissue.
Recovery bloodwork at week 6 post-PCT: total testosterone, free testosterone, LH, FSH, estradiol (sensitive LC-MS/MS assay), SHBG. Total T below 400 ng/dL with detectable LH indicates ongoing central recovery; below 300 ng/dL with suppressed LH at week 12 is the threshold for clinical intervention. Full recovery timeline: 3 months for moderate testosterone cycles, 6–9 months for nandrolone-containing protocols, 12+ months for multi-year suppression without hCG support.